Chemotherapy, Immunotherapy, PD-L1
Conditions
Brief summary
PD-L1 is identified as an important biomarkers for predicting PD-1/PD-L1 inhibitors in advanced Non-Small Cell Lung Cancer. Several previous clinical trials have demonstrated that chemotherapy could enhance the efficacy of PD-1/L1 immunotherapy in NSCLC such as Checkmate-227, Impower-150, Keynote-189, etc. Pre-clincial experiment shows that chemotherapy could increase CD8 TIL infiltration in tumor microenvironment, activate T cell immune reaction. However, it remains unclear whether chemotherapy could affect PD-L1 in advanced NSCLC patients. The present study aims to evaluate whether PD-L1 will change after receiving chemotherapy in advanced NSCLC patients.
Interventions
OTHERPD-L1 group
PD-L1 expression is evaluated using immunohistochemical assay
Sponsors
Baodong Qin
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Advanced NSCLC diagnosed histologically; Expected survival ≥ 6 month; * Without Druggable molecular events (EGFR, ALK, c-Met, BRAF, Ret, etc) * ECOG / PS score: 0-2, and the main organ function to meet the following criteria: HB ≥ 90g / L, ANC ≥ 1.5 × 109 / L, PLT ≥ 80 × 109 / L,BIL \<1.5 times the upper limit of normal (ULN); Liver ALT and AST \<2.5 × ULN and if liver metastases, ALT and AST \<5 × ULN; Serum Cr ≤ 1 × ULN, endogenous creatinine clearance ≥50ml/min
Exclusion criteria
* Patient can not comply with research program requirements or follow-up; * Patient will receive immunotherapy;
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with PD-L1 positive as assessed by immunohistochemical assay | through study completion, an average of 1 year | PD-L1 will be calculated using immunohistochemical assay |
Countries
China
Outcome results
None listed